INTRODUCTION
============

Historically, many species of insects or arthropods such as *Coleoptera, Hymenoptera, Orthoptera, and Lepidoptera* are important natural resources for human beings [@B001]. They can be consumed as food for humans or animals, and even used for medical purposes [@B002],[@B003]. Today, over 1500 species of insects are known to be consumed for edible material and harvested from nature in 113 countries [@B004].

Recent studies have shown that many insects have good nutritional content such as crude protein, unsaturated fatty acid, vitamins, mineral elements, and carbohydrate [@B005],[@B006]. For this reason, many researchers have paid increasing attention to them and examined the nutritional value of such insects and their role in human nutrition [@B007],[@B008]. In Korea, there has been increasing interest in the utility of insects as a new protein source, but no insects, except for *Bombyx mori* and *Oxya chinensis sinuosa*, can be produced as food ingredients and sold in a market due to non-registration on the Korean Food Standards Codex.

*A. dichotoma* is a species of rhinoceros beetle found in East Asia including China, Japan and Korea. The larvae have been used as a traditional medicine for the treatment of diabetes [@B003]. Many researchers reported that *A. dichotoma* larvae have various biologic effects including antineoplastic and antihepatotoxic properties [@B009]-[@B011]. Based on the previous literature, *A. dichotoma* larva is considered a valuable source of nutritious food for people. Despite its diverse biological activities, the subchronic oral toxicity of *A. dichotoma* larvae has not been evaluated so far. Thus the present study was designed to support its safety for human use by performing a 13-wks repeated oral toxicity test in SD rats under the GLP regulations of the Organization for Economic Cooperation and Development (OECD) and the Korea Ministry of Food and Drug Safety (MFDS). The protocol of the study was reviewed by the Institutional Animal Care and Use Committee (IACUC) of the Korea Institute of Toxicology (KIT), which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

MATERIALS AND METHODS
=====================

***Animal and maintenance.*** Male and female specific pathogen-free Sprague-Dawley rats (Crl:CD(SD)) from Orient Bio Co. (Seongnam, Korea) were approximately 5 wks of age at study start. The animals were acclimatized for 7 days, and then healthy animals were randomly assigned to four groups (vehicle control, 250, 850 and 2500 mg/kg/day group, 10 animals/sex/group) with additional recovery groups (5 animals/sex/Vehicle control and 2500 mg/kg/day group). Rats were housed two animals per cage for the pretreatment and treatment period in a stainless steel wire cage (255W × 465L × 200H mm). A commercial pellet diet (PMI nutrition International, USA) and sterilized tap water were provided *ad libitum*. The testing facility provided appropriate environmental conditions (23 ± 3℃ room temperature, 12 hr light/dark cycle, 30\~70% relative humidity, 150\~ 300 lux, 10\~20 air ventilation/hr), and cage rack location within the animal room was rotated weekly.

***Preparation of the freeze-dried powder of *A. dichotoma* larvae (fdADL) and analysis.*** The fdADL, ground to a powder and sterilized, was provided by World Way Co. (Yeongi, Korea). Analysis of proximate composition revealed that *A. dichotoma* larvae contained 38.17 ± 0.48% crude protein, 32.72 ± 0.76% crude fat, 4.14 ± 0.04% crude ash, 22.73 ± 0.42% carbohydrate, and 2.25 ± 0.01% moisture. The predominant fatty acids in *A. dichotoma* larvae consist of monounsaturated fatty acid (57.70%) such as oleic acid, followed by saturated fatty acids (36.00%) and polyunsaturated fatty acids (6.50%). Oleic acid (19.13%) was the most abundant fatty acid and marker compound followed by palmitic acid (12.52%), palmitoleic acid (3.71%) and linoleic acid (2.08%) in 100 g of *A. dichotoma* larvae on a dry weight basis [@B012].

***Formulation of fdADL.*** The appropriate quantity of fdADL was weighed, and mixed with sterile distilled water (Dai Han Pharm., Korea) for the high dose preparation. The low and middle dose formulations were prepared by diluting the high dose formulation with sterile distilled water. The dose formulations were prepared daily.

***Dose levels selection.*** Based on the results of a previous 4 wks dose toxicity study, the dose of 2500 mg/kg/day was selected as the high dose for this study and the middle and low doses as 850 and 250 mg/kg/day, respectively. In addition, sterilized distilled water was administered to the vehicle control group.

***Clinical observation, body weight, food consumption and ophthalmologic examination.*** All animals were clinically observed twice daily except once a day throughout the study period. In addition, detailed clinical observations were conducted once a week during the treatment and recovery period for abnormal behavior and appearance. Individual body weights were measured before dosing on the first day of dosing and once per week thereafter. Final body weight was measured on the day of necropsy. Cage food consumption was recorded once weekly during the treatment and recovery periods. Individual food consumption was calculated as g/rat/day. Ophthalmic examination was performed on all animals on week 13.

***Clinical pathological examination.***

***Hematological analysis:*** At termination, approximate 1.5 mL of blood was collected from cauda vena cava of the animals under deep isoflurane anesthesia prior to necropsy. For hematology evaluation, white blood cell (WBC), red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet (PLT), reticulocyte (RET), differential leucocyte such as neutrophil (NEU), lymphocyte (LYM), eosinophil (EOS), monocyte (MON), and basophil (BAS) were analyzed with ADVIA 2120i hematology analyzer (Siemens, USA). Also, prothrombin time (PT) and Activated partial thromboplastin time (APTT) were analyzed with ACL 9000 coagulation analyzer (Instrumentation Laboratory, Italy).

***Clinical chemistry analysis:*** At termination, approximate 3 mL of blood was collected from cauda vena cava for their anesthetic states. Whole blood was placed at ambient room temperature for at least 30 min and centrifuged (3000 rpm, 10 min, room temperature) and serum then was separated. For clinical chemistry evaluation, glucose (GLU), blood urea nitrogen (BUN), creatinine (CREA), total protein (TP), albumin (ALB), albumin/globulin ratio (A/G), total cholesterol (TCHO), triglyceride (TG), phospholipid (PL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphate (ALP), total bilirubin (TBIL), chloride (Cl), creatine phosphokinase (CK), inorganic phosphorus (IP), sodium (Na), potassium (K) and gamma glutamyl transpeptidase (GGT) were measured with Toshiba 200FR NEO chemistry analyzer (Toshiba Co., Japan).

***Urinalysis:*** Before termination, all animals were restricted from diet but not water, and urine were collected overnight (approximately 16 hrs) using with metabolic cages. For urinalysis evaluation, volume (VOL), color (COL), clarity (CLA), pH, specific gravity (SG), bilirubin (BIL), protein (PRO), urobilinogen (UBG), nitrite (NIT), glucose (GLU), erythrocyte (ERY) and ketone (KET) were analyzed with Combur 10 TM urine sticks (Roche, Germany) and Cobas U411 urine analyzer (Roche, Germany). Also, microscopic examination was conducted for sediments such as epithelial cell, red blood cell and white blood cell.

***Terminal procedures.*** After anesthesizing by isoflurane inhalation and euthanizing by exsanguination on all animals, a full macroscopic examination (abdominal, thoracic and cranial cavities, *etc*) was performed. Absolute organ weights of brain, pituitary gland, liver, spleen, heart, thymus, salivary gland, prostate, seminal vesicles with coagulation glands), adrenal glands, testes, epididymides, lung, thyroid (with parathyroids), uterus (with cervix), ovaries (with oviduct) and kidneys were calculated, along with the relative organ weights as a percentage of the terminal body weight.

Following a detailed external and internal examination, all tissues were taken from each animal. With the exception of the testes and epididymides, all tissues were preserved in a 10% neutral buffered formalin solution. The testes and epididymides were fixed in Bouin's fixative for approximately 48 hrs before being transferred to 70% alcohol. The tissues were processed, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E) under standard histological methods prior to microscopic examination. All preserved tissues from the animals in the vehicle control and high dose group were examined.

***Allergy response.*** At termination, approximate 0.6 mL of blood was collected from cauda vena cava for their anesthetic states. Whole blood was stored at ambient room temperature for at least 30 min and centrifuged (13200 rpm, 3 min, room temperature) and then serum was separated. Serum IgE and histamine levels were measured with IgE (Rat) ELISA kit (Abnova Corporation, Taiwan) and Histamine ELISA kit (Abnova Corporation, Taiwan). Data analysis and calculation were conducted with SOFTmax Pro Ver. 5.4.1 (Molecular Devices Corp., USA).

***Statistical analysis.*** Variance of homogeneity for different dose groups was examined using the Bartlett's Test. Homogeneous data was analyzed using the Analysis of Variance (ANOVA) and the significance of inter-group differences was analyzed using Dunnett's Test. Heterogeneous data were analyzed using Kruskal-Wallis Test and the significance of inter-group differences between the control and treated groups was assessed using Dunn's Rank Sum Test.

For comparing control group and recovery group, the data was analyzed for homogeneity for variance using F-test. Homogeneity data was analyzed using T-test and the significant difference between control and recovery group was assessed using Dunnett's Test. Heterogeneous data was analyzed using Kruskal-Wallis Test and significant difference between control and recovery group was assessed using Dunn's Rank Sum Test.

The statistical analyses were performed by comparing the dose groups to the vehicle control group using the Path/Tox system. The results of the comparisons are only indicated when p-values of less than 0.05 or 0.01 were attained.

RESULTS
=======

***Clinical observations, body weight, food consumption, and ophthalmologic examination.*** There were no treatment-related mortality or clinical signs in either sex of any groups during the study period. Body weight and food consumption also showed no differences between the vehicle control group and the treated groups. In ophthalmologic examination, no abnormal findings were observed in either sex of any group. The body weight and food consumption changes are presented in [Fig. 1](#F001){ref-type="fig"} and [2](#F002){ref-type="fig"}, respectively.

![Mean body weight of male (left) and female (right) SD rats orally administered with fdADL during the study period.](toxicr-31-69-g001){#F001}

![Mean food consumption of male (left) and female (right) SD rats orally administered with fdADL during the study period.](toxicr-31-69-g002){#F002}

***Clinical pathological examination.*** No significant changes in urinalysis parameters were observed in either sex of any groups (data not shown). In addition, there were no treatment-related changes in hematology ([Table 1](#T001){ref-type="table"}) or clinical chemistry ([Table 2](#T002){ref-type="table"}) in either sex of any groups. In hematology, statistically significant decrease in relative lymphocyte count (LYM) was noted in males at 2500 mg/kg/day on week 13, but this was considered incidental since there were no microscopic correlates and the value was within normal range [@B013].

###### Haematology mean values in male and female SD rats orally administered with fdADL for 13 wks

  ------------------ --------------- -------------- -------------- ----------------- -------------- -------------- -------------- --------------
  Sex                Male            Female                                                                                       
                                                                                                                                  
  Dose (mg/kg/day)   0               250            850            2500              0              250            850            2500
                                                                                                                                  
  No. of animals     10              10             10             10                10             10             10             10
                                                                                                                                  
  WBC (× 10^3^/μL)   10.14 ± 2.765   8.99 ± 2.240   9.69 ± 1.988   8.24 ± 1.902      6.58 ± 2.185   5.72 ± 2.030   6.86 ± 1.058   6.71 ± 2.737
  RBC (× 10^6^/μL)   8.95 ± 0.314    8.97 ± 0.344   9.05 ± 0.564   8.74 ± 0.493      8.26 ± 0.355   8.36 ± 0.473   8.19 ± 0.185   8.42 ± 0.371
  HGB (g/dL)         15.4 ± 1.13     15.8 ± 0.54    15.9 ± 0.98    15.5 ± 0.71       15.7 ± 0.64    15.8 ± 0.51    15.4 ± 0.52    15.8 ± 0.70
  HCT (%)            47.2 ± 1.78     47.5 ± 1.57    49.1 ± 2.89    46.7 ± 2.58       46.6 ± 2.10    47.3 ± 2.02    46.3 ± 1.96    47.1 ± 2.28
  MCV (fL)           52.8 ± 1.22     53.0 ± 1.35    54.3 ± 1.63    53.4 ± 1.20       56.4 ± 1.35    56.6 ± 2.14    45.5 ± 2.06    56.0 ± 1.64
  MCH (pg)           17.2 ± 1.11     17.6 ± 0.58    17.6 ± 1.28    17.7 ± 0.53       19.0 ± 0.45    18.9 ± 0.78    18.8 ± 0.53    18.7 ± 0.35
  MCHC (g/dL)        32.6 ± 2.00     33.2 ± 0.40    32.4 ± 1.79    33.2 ± 0.59       33.7 ± 0.37    33.4 ± 0.57    33.3 ± 0.67    33.4 ± 0.60
  PLT (× 10^3^/μL)   1095 ± 115.8    1008 ± 74.5    979 ± 90.8     1019 ± 96.4       1139 ± 123.6   998 ± 74.0     1051 ± 95.3    1054 ± 155.0
  RET (%)            1.87 ± 0.385    1.83 ± 0.204   1.83 ± 0.379   1.90 ± 0.279      2.22 ± 0.207   1.89 ± 0.349   2.20 ± 0.472   1.96 ± 0.480
  NEU (%)            11.8 ± 3.33     14.3 ± 5.25    16.4 ± 11.70   19.3 ± 7.13       11.2 ± 2.69    11.4 ± 4.53    10.5 ± 3.73    13.3 ± 4.55
  LYM (%)            83.5 ± 3.58     79.8 ± 4.46    78.0 ± 12.08   74.1 ± 8.50^\*^   82.5 ± 2.75    82.0 ± 4.88    84.1 ± 3.99    81.0 ± 4.66
  EOS (%)            1.1 ± 0.27      1.3 ± 0.42     1.2 ± 0.26     1.4 ± 0.44        1.4 ± 0.41     1.2 ± 0.26     1.3 ± 0.45     1.6 ± 0.43
  MON (%)            2.6 ± 0.72      3.1 ± 0.61     3.2 ± 1.02     4.0 ± 1.88        3.7 ± 1.27     4.1 ± 1.59     2.9 ± 1.03     3.0 ± 1.28
  BAS (%)            0.3 ± 0.11      0.3 ± 0.11     0.4 ± 0.12     0.2 ± 0.13        0.4 ± 0.15     0.4 ± 0.13     0.3 ± 0.11     0.3 ± 0.08
  LUC (%)            0.7 ± 0.25      1.2 ± 1.51     0.7 ± 0.18     1.1 ± 0.77        0.9 ± 0.20     0.9 ± 0.43     0.9 ± 0.21     0.9 ± 0.38
  PT (sec)           13.4 ± 0.46     13.4 ± 0.67    13.7 ± 0.89    13.4 ± 0.67       13.3 ± 0.53    13.4 ± 0.70    13.4 ± 0.35    13.8 ± 0.44
  APTT (sec)         17.9 ± 1.09     17.8 ± 1.39    17.4 ± 1.94    17.0 ± 1.30       15.3 ± 2.28    14.6 ± 1.92    15.1 ± 1.71    14.5 ± 1.38
  ------------------ --------------- -------------- -------------- ----------------- -------------- -------------- -------------- --------------

Values are means ± S.D.

^\*^: Significant differences from vehicle control group (*p*\<0.05).

###### Clinical chemistry values in male and female SD rats orally administered with fdADL for 13 wks

  ----------------- ---------------- ------------------ ---------------- ---------------- ---------------- ------------------ ---------------- ----------------
  Sex               Male             Female                                                                                                    
                                                                                                                                               
  Dose(mg/kg/day)   0                250                850              2500             0                250                850              2500
                                                                                                                                               
  No. of animals    10               10                 10               10               10               10                 10               10
                                                                                                                                               
  GLU (mg/dL)       105.4 ± 15.59    92.0 ± 15.08       108.9 ± 15.90    111.7 ± 32.70    119.2 ± 16.34    118.3 ± 30.87      129.2 ± 20.75    110.1 ± 22.98
  BUN (mg/dL)       13.5 ± 1.64      15.1 ± 1.64        14.5 ± 1.74      14.0 ± 2.64      17.7 ± 2.65      17.5 ± 3.26        17.1 ± 2.66      18.1 ± 1.77
  CREA (mg/dL)      0.46 ± 0.039     0.49 ± 0.036       0.46 ± 0.049     0.51 ± 0.061     0.58 ± 0.086     0.60 ± 0.064       0.60 ± 0.086     0.60 ± 0.044
  TP (g/dL)         6.98 ± 0.226     6.89 ± 0.303       6.96 ± 0.280     6.78 ± 0.216     7.83 ± 0.292     7.87 ± 0.627       7.79 ± 0.451     7.66 ± 0.345
  ALB (g/dL)        4.43 ± 0.074     4.43 ± 0.153       4.40 ± 0.162     4.36 ± 0.157     5.06 ± 0.276     5.10 ± 0.363       5.09 ± 0.272     4.92 ± 0.254
  TCHO (mg/dL)      60.3 ± 10.45     70.2 ± 18.41       65.6 ± 15.51     63.3 ± 9.01      94.0 ± 15.10     90.1 ± 18.82       83.7 ± 9.99      86.4 ± 14.99
  TG (mg/dL)        46.3 ± 15.61     49.4 ± 22.48       55.2 ± 13.96     41.8 ± 5.28      51.0 ± 17.41     44.7 ± 19.65       41.2 ± 10.73     42.5 ± 18.87
  PL (mg/dL)        92 ± 10.7        104 ± 24.8         100 ± 14.9       96 ± 10.3        174 ± 21.5       166 ± 28.7         160 ± 16.7       158 ± 18.7
  AST (IU/L)        122.9 ± 17.96    149.8 ± 51.60      119.2 ± 31.72    126.3 ± 15.26    128.5 ± 30.20    121.6 ± 21.93      111.3 ± 13.14    143.1 ± 47.64
  ALT (IU/L)        31.0 ± 4.00      45.9 ± 32.09       31.7 ± 7.27      28.8 ± 4.11      41.7 ± 18.18     32.3 ± 13.62       30.3 ± 8.87      52.9 ± 36.86
  TBIL (mg/dL)      0.118 ± 0.0220   0.118 ± 0.0216     0.116 ± 0.0112   0.106 ± 0.0134   0.148 ± 0.0319   0.140 ± 0.0219     0.152 ± 0.0319   0.144 ± 0.0302
  ALP (IU/L)        258.4 ± 53.57    275.9 ± 55.03      234.8 ± 32.58    224.1 ± 38.94    115.7 ± 33.16    111.9 ± 27.01      106.4 ± 25.69    112.9 ± 27.00
  CK (IU/L)         621 ± 117.0      673 ± 163.0        570 ± 249.2      586 ± 165.7      559 ± 217.9      589 ± 121.8        517 ± 158.7      518 ± 153.2
  GGT (IU/L)        0.02 ± 0.076     0.27 ± 0.272^\*^   0.01 ± 0.015     0.16 ± 0.206     0.29 ± 0.310     0.04 ± 0.126^\*^   0.09 ± 0.208     0.23 ± 0.383
  ----------------- ---------------- ------------------ ---------------- ---------------- ---------------- ------------------ ---------------- ----------------

Values are means ± S.D.

^\*^: Significant differences from vehicle control group (*p*\<0.05).

In clinical pathology, a statistically changes in GGT were noted in male and female at 250 mg/kg/day on week 13, respectively. These changes were considered incidental since they showed no dose-related pattern and were inconsistent between sexes.

***Organ weights, macro and microscopic examination.*** Absolute organ weight data is presented in [Table 3](#T003){ref-type="table"}. Relative organ weights data as a percentage of body weight is not presented. There were no treatment-related effects observed between vehicle control and treated groups for any organ weight parameters. In addition, no treatmentrelated macroscopic findings were observed for any treated groups in the study (data not shown).

###### Absolute organ weights in male and female SD rats orally administered with fdADL for 13 wks

  ------------------------- --------------- --------------- --------------- --------------- -------------- -------------- -------------- --------------
  Sex                       Male            Female                                                                                       
                                                                                                                                         
  Dose(mg/kg/day)           0               250             850             2500            0              250            850            2500
                                                                                                                                         
  No. of animals            10              10              10              10              10             10             10             10
                                                                                                                                         
  Brain (g)                 2.16 ± 0.073    2.12 ± 0.156    2.18 ± 0.086    2.10 ± 0.077    2.00 ± 0.051   1.98 ± 0.071   1.96 ± 0.070   1.97 ± 0.133
  Pituitary gland (g)       0.01 ± 0.002    0.01 ± 0.002    0.01 ± 0.002    0.01 ± 0.001    0.02 ± 0.007   0.02 ± 0.004   0.02 ± 0.004   0.02 ± 0.004
  Liver (g)                 14.23 ± 1.148   13.89 ± 1.131   14.67 ± 1.686   13.76 ± 1.499   8.40 ± 0.847   8.23 ± 1.259   8.39 ± 1.101   8.41 ± 0.568
  Spleen (g)                0.81 ± 0.111    0.78 ± 0.083    0.87 ± 0.114    0.79 ± 0.155    0.57 ± 0.054   0.56 ± 0.076   0.53 ± 0.047   0.56 ± 0.069
  Heart (g)                 1.54 ± 0.104    1.52 ± 0.129    1.58 ± 0.181    1.53 ± 0.285    1.06 ± 0.090   1.04 ± 0.099   1.02 ± 0.144   1.02 ± 0.058
  Thymus (g)                0.41 ± 0.060    0.38 ± 0.083    0.40 ± 0.060    0.35 ± 0.085    0.30 ± 0.036   0.31 ± 0.053   0.33 ± 0.088   0.33 ± 0.050
  Salivary glands (g)       0.77 ± 0.065    0.78 ± 0.073    0.83 ± 0.139    0.73 ± 0.099    0.50 ± 0.048   0.49 ± 0.045   0.48 ± 0.062   0.51 ± 0.046
  Prostate (g)              0.70 ± 0.122    0.68 ± 0.090    0.71 ± 0.174    0.63 ± 0.126    \-             \-             \-             \-
  Kidneys (g)               3.63 ± 0.311    3.44 ± 0.204    3.86 ± 0.544    3.53 ± 0.516    2.26 ± 0.268   2.13 ± 0.240   2.12 ± 0.224   2.13 ± 0.117
  Adrenal glands (g)        0.06 ± 0.007    0.06 ± 0.011    0.06 ± 0.009    0.06 ± 0.009    0.08 ± 0.008   0.07 ± 0.009   0.07 ± 0.014   0.08 ± 0.010
  Testes (g)                3.41 ± 0.245    3.48 ± 0.256    3.37 ± 0.319    3.24 ± 0.170    \-             \-             \-             \-
  Epididymides (g)          1.58 ± 0.098    1.57 ± 0.128    1.64 ± 0.166    1.51 ± 0.097    \-             \-             \-             \-
  Lung (g)                  1.76 ± 0.072    1.69 ± 0.138    1.68 ± 0.154    1.78 ± 0.568    1.38 ± 0.116   1.34 ± 0.122   1.31 ± 0.141   1.40 ± 0.144
  Thyroid/Parathyroid (g)   0.03 ± 0.004    0.03 ± 0.003    0.03 ± 0.003    0.03 ± 0.003    0.02 ± 0.003   0.02 ± 0.006   0.02 ± 0.006   0.02 ± 0.005
  Seminal vesicle (g)       2.15 ± 0.278    2.08 ± 0.254    2.11 ± 0.432    2.14 ± 0.302    \-             \-             \-             \-
  Uterus/cervix (g)         \-              \-              \-              \-              0.73 ± 0.177   0.61 ± 0.163   0.65 ± 0.235   0.61 ± 0.144
  Ovaries/oviduct (g)       \-              \-              \-              \-              0.13 ± 0.017   0.12 ± 0.012   0.13 ± 0.022   0.14 ± 0.015
  ------------------------- --------------- --------------- --------------- --------------- -------------- -------------- -------------- --------------

Values are means ± S.D.

In microscopic observation, no treatment-related findings were observed in the high dose group. The histopathological findings observed in some tissues at 2500 mg/kg/day were consistent with common background findings in rats of this age [@B014]. The tissues with high incidence are presented ([Table 4](#T004){ref-type="table"}).

###### Summary incidence microscopic findings in male and female SD rats orally administered with fdADL for 13 wks

  --------------------------------- ---------- ------------ ---- ------
  Sex                               Male (n)   Female (n)        
                                                                 
  Dose(mg/kg/day)                   0          2500         0    2500
                                                                 
  No. of animals                    10         10           10   10
                                                                 
  Kidney                                                         
  Mineralization                    3          1            3    4
  Tubular basophilia                7          5            1    0
  Cystic tubules                    1          2            0    1
  Liver                                                          
  Infiltration, mononuclear cells   8          10           5    7
  Vacuolated area                   1          2            2    1
  Heart                                                          
  Cardiomyopathy                    3          5            0    0
  Lung with bronchi                                              
  Alveolar macrophage               2          2            0    0
  Adrenal glands                                                 
  Cortical vacuolation              5          6            0    0
  Harderian glands                                               
  Pigment                           8          10           8    6
  Stomach                                                        
  Dilated gland                     2          2            1    1
  Prostate                                                       
  Infiltration, mononuclear cells   5          6            \-   \-
  --------------------------------- ---------- ------------ ---- ------

***Allergy response.*** No significant changes in serum IgE levels were observed in either sex of any groups. In histamine measurement, the samples of both sexes showed a slight increase along with rise of dosing concentration (male: 1.1-1.4 fold, female: 1.1-1.6 fold); however, statistical significance was observed only in females at 2500 mg/ kg/day on week 13 and recovery week 4 ([Table 5](#T005){ref-type="table"}).

###### Serum IgE and histamine levels in male and female SD rats orally administered with fdADL

  ---------------- ----------------- -------------- ------------------- ------------------ ------------------
  Sex              Dose(mg/kg/day)   IgE (ng/mL)    Histamine (ng/mL)                      
                                                                                           
  Dosing group     Recovery group    Dosing group   Recovery group                         
                                                                                           
  No. of animals                     10             5                   10                 5
  Male             0                 23.9 ± 11.9    15.1 ± 12.7         111.9 ± 26.4       102.1 ± 31.8
                   250               12.3 ± 6.6     NA                  123.1 ± 40.4       NA
                   850               18.4 ± 12.4    NA                  142.7 ± 35.7       NA
                   2500              28.2 ± 32.5    11.9 ± 7.7          152.9 ± 67.6       140.0 ± 61.3
  Female           0                 12.5 ± 10.1    10.8 ± 7.3          85.7 ± 21.3        99.7 ± 45.5
                   250               34.1 ± 56.2    NA                  96.2 ± 23.1        NA
                   850               20.7 ± 24.0    NA                  100.6 ± 18.4       NA
                   2500              10.3 ± 6.2     26.1 ± 23.9         126.2 ± 43.8^\*^   159.3 ± 28.0^\*^
  ---------------- ----------------- -------------- ------------------- ------------------ ------------------

Values are means ± S.D.

NA: not applicable schedule, ^\*^: Significant differences from vehicle control group (*p*\<0.05).

DISCUSSION
==========

Eating of insect as food has been a common practice in human history all over the world. This food culture dates back to prehistory and is still traditional in many countries [@B015],[@B016]. As the world population continues to grow rapidly, edible insects have received more attention recently, especially in terms of how to develop insects as a sustainable and economic food source in the interest of food security [@B006]. The nutritional value of edible insects has been stated in many scientific publications. They are known to provide sources of proteins and rich fat comparable to animals [@B017].

However, safety issue of edible insects is one of the most important considerations when developing the materials into any diet because they can cause severe toxic symptoms or even death in humans after ingestion. Insects may contain harmful materials to human in their bodies in order to protect themselves from natural enemies. Thus, ingestion of insects has potential hazards such as nutritional losses, dyspepsia, tumorigenic metabolites, and allergic reactions [@B018]. It was also reported that eating of *Eucheirasocialis* (Pieridae) pupae occasionally caused vomiting and headaches in humans, and ingestion of *Anaphe* spp. caterpillars displayed ataxic syndrome [@B019]-[@B021].

*A. dichotoma* and its larvae are very popular as one of pet insects in Korea. However its use as food or food additive has been prohibited formally because of lack of toxicological information in humans. Thus, we conducted the 13 wks oral toxicity study of *A. dichotoma* larvae as part of human safety program for toxicological assessment.

In the present study, there were no treatment-related adverse changes or findings in any parameters, when compared to control group. Although some statistically significant differences in the toxicological parameters were observed, these changes were considered to be incidental or in the range of basal area since they were no dose-dependent or inconsistent between the sexes. These results correlate to those of our previous toxicity study of another edible insect, *Tenebrio molito*r larvae [@B022]. For the results of histamine and IgE levels, it was not considered to be meaningfully involved in the allergy response of *A. dichotoma* larvae although statistical significance on serum histamine level was observed in female group, but not in male group, with 2500 mg/kg/day group at week 13 and recovery week 4. The increased level of histamine in 2500 mg/kg/day dose of female group was not outrageous compared to same dose of male group. Those increases showed less than 2-fold, compare to vehicle control group of this study as well as previously reported data about naïve histamine range in rat bloods [@B023],[@B024]. Moreover, the statistical significance at 2500 mg/ kg/day group in histamine levels could not be considered to imply a biological significance in an allergic manifestation without the accompanied increase of serum IgE levels [@B025]. In fact, overall research articles showed huge differences, from several fold to several hundred fold greater, to demonstrate the correlation between the increase of histamine and IgE levels and allergic response [@B025]-[@B027]. Therefore, it was difficult to identify allergic response by using a mere increase rate of histamine levels in the present study.

In conclusion, oral administration of the freeze-dried powder from *A. dichotoma* larvae for 13 wks produced no adverse effects in SD rats given up to 2500 mg/kg/day; therefore, the NOAEL was established to be 2500 mg/kg/ day or more under this experimental condition.
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